Successful Allogeneic CD34 Hematopoietic Stem Cell Boost for Prolonged Cytopenias Following CAR T-cell Therapy in B-cell Acute Lymphoblastic Leukemia. On Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2024 Nov 17

PMID 39551836

Authors

Agueda Molinos-Quintana

Nuria Martinez-Cibrian

Anna Alonso-Saladrigues

Victor Galan-Gomez

Rebeca Bailen

Susana Buendia-Lopez

Carolina Fuentes-Socorro

Mi Kwon

Marta Gonzalez-Vincent

Concepcion Perez de Soto

Berta Gonzalez-Martinez

Susana Rives

Jose Maria Perez-Hurtado

Valentin Ortiz-Maldonado

Jose Antonio Perez-Simon

Affiliations

Soon will be listed here.

References

Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T . Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4(15):3776-3787. PMC: 7422135. DOI: 10.1182/bloodadvances.2020002509. View

Cordas Dos Santos D, Tix T, Shouval R, Gafter-Gvili A, Alberge J, Cliff E . A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024; 30(9):2667-2678. PMC: 11765209. DOI: 10.1038/s41591-024-03084-6. View

Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P . Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023; 142(10):865-877. DOI: 10.1182/blood.2023020578. View

Jain T, Olson T, Locke F . How I treat cytopenias after CAR T-cell therapy. Blood. 2023; 141(20):2460-2469. PMC: 10646792. DOI: 10.1182/blood.2022017415. View

Gagelmann N, Wulf G, Duell J, Glass B, Heteren P, von Tresckow B . Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study. Blood Adv. 2022; 7(4):555-559. PMC: 9984300. DOI: 10.1182/bloodadvances.2022008042. View

Rejeski K, Greco R, Onida F, Sanchez-Ortega I, Bonini C, Sureda A . An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA. Hemasphere. 2023; 7(5):e889. PMC: 10145722. DOI: 10.1097/HS9.0000000000000889. View

Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L . CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021; 138(24):2499-2513. PMC: 8893508. DOI: 10.1182/blood.2020010543. View

Rejeski K, Burchert A, Iacoboni G, Sesques P, Fransecky L, Bucklein V . Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv. 2022; 6(16):4719-4725. PMC: 9631678. DOI: 10.1182/bloodadvances.2022007776. View

Mullanfiroze K, Lazareva A, Chu J, Williams L, Burridge S, Silva J . CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. Blood Adv. 2022; 6(16):4715-4718. PMC: 9631677. DOI: 10.1182/bloodadvances.2022007572. View

10.

Lipsitt A, Beattie L, Harstead E, Li Y, Goorha S, Maron G . Allogeneic CD34 selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection. Pediatr Blood Cancer. 2022; 70(3):e30166. DOI: 10.1002/pbc.30166. View

11.

Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N . Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. J Immunother Cancer. 2023; 11(4). PMC: 10124318. DOI: 10.1136/jitc-2022-006406. View

12.

Bethge W, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B . GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022; 140(4):349-358. DOI: 10.1182/blood.2021015209. View